Department of Emergency Medicine, Emergency University Hospital, Bucharest, Romania
Search for other papers by Irina-Anca Eremia in
Google Scholar
PubMed
Department of Orthopaedics and Traumatology, Emergency University Hospital Bucharest, Romania
Search for other papers by Bogdan Serban in
Google Scholar
PubMed
Department of Orthopaedics and Traumatology, Emergency University Hospital Bucharest, Romania
Search for other papers by Mihnea Popa in
Google Scholar
PubMed
Search for other papers by Adela Iancu in
Google Scholar
PubMed
Department of Emergency Medicine, Emergency University Hospital, Bucharest, Romania
Search for other papers by Silvia Nica in
Google Scholar
PubMed
Department of Orthopaedics and Traumatology, Emergency University Hospital Bucharest, Romania
Search for other papers by Catalin Cirstoiu in
Google Scholar
PubMed
-
Renal cell carcinoma (RCC) is a common type of tumor that can develop in the kidney. It is responsible for around one-third of all cases of neoplasms. RCC manifests itself in a variety of distinct subtypes. The most frequent of which is clear cell RCC, followed by papillary and chromophobe RCC.
-
RCC has the potential for metastasis to a variety of organs; nevertheless, bone metastases are one of the most common and potentially fatal complications. These bone metastases are characterized by osteolytic lesions that can result in pathological fractures, hypercalcemia, and other complications, which can ultimately lead to a deterioration in quality of life and an increase morbidity.
-
While nephrectomy remains a foundational treatment for RCC, emerging evidence suggests that targeted therapies, including tyrosine kinase inhibitors and T cell checkpoint inhibitors, may offer effective alternatives, potentially obviating the need for adjuvant nephrectomy in certain cases of metastatic RCC
-
Bone metastases continue to be a difficult complication of RCC, which is why more research is required to enhance patient outcome.
Search for other papers by Andrea Angelini in
Google Scholar
PubMed
Search for other papers by Ivan Bohacek in
Google Scholar
PubMed
Search for other papers by Mihovil Plecko in
Google Scholar
PubMed
Search for other papers by Carlo Biz in
Google Scholar
PubMed
Search for other papers by Giulia Trovarelli in
Google Scholar
PubMed
Search for other papers by Mariachiara Cerchiaro in
Google Scholar
PubMed
Search for other papers by Giuseppe Di Rubbo in
Google Scholar
PubMed
Search for other papers by Pietro Ruggieri in
Google Scholar
PubMed
Purpose
-
Primary bone tumors of the fibula are rare. Distal fibular resection has a significant impact on ankle biomechanics and gait, possibly leading to complications such as ankle instability, valgus deformity, and degenerative changes. Question: Is there a need for reconstructive surgery after distal fibular resection, and what reconstructive procedures are available?
Materials and methods
-
The review is registered with the PROSPERO International Register of Systematic Reviews. Inclusion criteria consisted of all levels of evidence, human studies, patients of all ages and genders, publication in English, and resection of the distal portion of the fibula due to tumor pathology. The reviewers defined four different categories of interest by method of treatment. Additional articles of interest during full-text review were also added.
Results
-
The initial search resulted with a total of 2958 records. After screening, a total of 50 articles were included in the study. Articles were divided into ‘No reconstruction’, ‘Soft tissue reconstruction’, ‘Bone and soft tissue reconstruction’, and ‘Arthrodesis, arthroplasty or other reconstruction options’ groups.
Conclusion
-
Limb salvage surgery should be followed by reconstruction in order to avoid complications. Soft tissue reconstructions should always be considered to stabilize the joint after fibular resection. Bone reconstruction with reversed vascularized fibula is the preferred technique in young patients and in cases of bone defects more than 3 cm, while arthrodesis should be considered in adult patients. Whenever possible for oncologic reason, if a residual peroneal malleolus could be preserved, we prefer augmentation with a sliding ipsilateral fibular graft.
Search for other papers by Elisa Pala in
Google Scholar
PubMed
Search for other papers by Giulia Trovarelli in
Google Scholar
PubMed
Search for other papers by Andrea Angelini in
Google Scholar
PubMed
Search for other papers by Maria Chiara Cerchiaro in
Google Scholar
PubMed
Search for other papers by Pietro Ruggieri in
Google Scholar
PubMed
-
The best treatment of unicameral bone cyst and aneurismatic bone cyst (ABC) is debated in the literature.
-
For simple bone cysts, multiple treatments were proposed from observation only to open curettage. The historical treatment with intraosseous injection of methylprednisolone acetate into the bone cysts nowadays is reduced due to the morbidity of multiple injections and the risk of multiple pathologic fractures until the healing.
-
Different types of treatments for ABC are reported, including surgery, percutaneous treatments, and medical treatments; however, there is currently no consensus on the best approach. The association of curettage, bone graft, and elastic stable intramedullary nail (ESIN) had a success rate of over 85%. Decompressing the cyst wall is more critical for increasing the healing rate than the type of graft used to fill the cavity.
-
In ABC, sclerotherapy offers the advantages of lower invasiveness and morbidity, associated with better functional scores and faster return to full weight-bearing. Moreover, they can be used in challenging locations.
-
Selective arterial embolization is a complex procedure and often requires association with other treatments. Further studies are needed to confirm the effectiveness of denosumab and its side effects on skeletally immature patients. Curettage with adjuvants and autogenous bone grafting still shows promising results and can be used in larger, aggressive defects or superficial lesions.
-
For simple bone cysts, the combination of curettage, bone graft, and ESIN showed the best results. Sclerotherapy for ABC also shows promising results.
University of Basel, Basel, Switzerland
Search for other papers by Chengxiang Li in
Google Scholar
PubMed
The Bone and Soft Tissue Tumor Center of the University of Basel (KWUB), Basel, Switzerland
Search for other papers by Fatime Krasniqi in
Google Scholar
PubMed
Department of Radiology, University Hospital Basel, Basel, Switzerland
Search for other papers by Ricardo Donners in
Google Scholar
PubMed
Clarunis, University Digestive Health Care Center, St. Clara Hospital and University Hospital Basel, Switzerland
Search for other papers by Christoph Kettelhack in
Google Scholar
PubMed
The Bone and Soft Tissue Tumor Center of the University of Basel (KWUB), Basel, Switzerland
Search for other papers by Andreas H Krieg in
Google Scholar
PubMed
-
Synovial sarcoma is a rare and highly malignant soft tissue sarcoma. The inconspicuous and diversity of its early symptoms make it a highly misdiagnosed disease.
-
The management of synovial sarcomas is challenging as they are rare and have a poor prognosis. Early and correct diagnosis and treatment are critical for clinical outcomes. Misdiagnosis or delayed diagnosis can have devastating consequences for the patient.
-
The detection of SS18 gene rearrangement is considered a powerful tool in establishing the diagnosis of synovial sarcomas. Biopsies and testing for gene rearrangements are recommended for all patients in whom SS cannot be excluded.
-
Surgery is the mainstay of treatment for synovial sarcomas. Neoadjuvant/adjuvant radiotherapy is recommended for patients with big tumors (>5 cm) or positive resection margins, and neoadjuvant/adjuvant chemotherapy is recommended for patients with high-risk tumors or advanced diseases.
-
This article reviews synovial sarcomas from the perspectives of clinical and radiological presentation, histological and cytogenetic analysis, differential diagnosis, treatment, and prognosis.
Search for other papers by Serkan Bayram in
Google Scholar
PubMed
Search for other papers by Ahmet Salduz in
Google Scholar
PubMed
Search for other papers by Ahmet Müçteba Yıldırım in
Google Scholar
PubMed
Search for other papers by Korhan Özkan in
Google Scholar
PubMed
Search for other papers by Levent Eralp in
Google Scholar
PubMed
Search for other papers by Harzem Özger in
Google Scholar
PubMed
Background
-
The current systematic review aimed to answer the following questions: (i) Does extended curettage combined with the PMMA technique for the treatment of aggressive bone tumors around the knee led to the development of knee osteoarthritis? (ii) What factors are associated with osteoarthritis after bone cementation around the knee joint?
Methods
-
This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. All electronic searches were performed on November 20, 2022, by a single researcher who evaluated the full texts of potentially eligible studies to determine inclusion. In these patients, the presence of osteoarthritis secondary to the surgical procedure was investigated. Data extracted included study type, characteristics of participants, sample size, gender, tumor site (femur or tibia), secondary osteoarthritis, tumor volume, distance from the joint cartilage, reoperation, follow-up time, Campanacci grade, and pathological fracture.
Results
-
In total, 11 studies comprising 204 patients were evaluated, and it was found that 61 (30%) patients developed knee osteoarthritis due to extensive curettage and bone cement application for benign aggressive tumor treatment. According to the results obtained based the random effects model with the 11 studies included in the meta-analysis, the mean odds ratio of development knee OA with the 95% CI was calculated as −2.77 (−3.711, −1.83), which was statistically significant (z = −5.79; P < 0.000).
Conclusion
-
The association of distance between the tumor and joint cartilage and development of osteoarthritis was not shown in this meta-analysis.
Level of Evidence
-
Level IV prognostic study.
Search for other papers by Antal Imre in
Google Scholar
PubMed
Search for other papers by Sápi Zoltán in
Google Scholar
PubMed
Search for other papers by Szendrői Miklós in
Google Scholar
PubMed
-
Denosumab is a fully humanised monoclonal antibody to RANK ligand, inhibiting the RANK–RANKL pathway. It promotes the apoptosis of osteoclast-like giant cells, a secondary ossification and connective tissue formation.
-
Given its high efficacy, denosumab is the standard treatment of unresectable or metastatic giant cell tumour of bone (GCTB) requiring morbid surgery.
-
Neoadjuvant administration of denosumab may be justified to enable the resection of the tumour in certain cases; it should be considered, however, with caution for joint-saving surgery due to high local recurrence rates.
-
In cases of unresectable or metastatic GCTB, however, denosumab treatment should be administered for years or even as a lifelong therapy. This poses many yet unanswered questions concerning the frequency of denosumab treatment as well as the ratio of the adverse events in the following years.
-
Denosumab suppresses, not directly targets, the neoplastic stromal cells of GCTB. Ongoing in vitro studies suggest that other drugs alone or in combination (e.g. sunitinib) with denosumab may target both the neoplastic and the giant cells.
-
Promising results have been reported regarding the off-label use of denosumab in other giant cell-rich tumours/tumour-like lesions, i.e. aneurysmal bone cysts and central giant cell granulomas. Data are derived, however, mostly from case reports and case series. Large prospective clinical trials are needed to evaluate the role and also the side effects of denosumab in the treatment of these rare diseases.
University Emergency Hospital Bucharest, Romania
Search for other papers by Bogdan Serban in
Google Scholar
PubMed
University Emergency Hospital Bucharest, Romania
Search for other papers by Bogdan Cretu in
Google Scholar
PubMed
University Emergency Hospital Bucharest, Romania
Search for other papers by Adrian Cursaru in
Google Scholar
PubMed
Elias University Emergency Hospital, Bucharest, Romania
Search for other papers by Cornelia Nitipir in
Google Scholar
PubMed
Elias University Emergency Hospital, Bucharest, Romania
Search for other papers by Cristina Orlov-Slavu in
Google Scholar
PubMed
University Emergency Hospital Bucharest, Romania
Search for other papers by Catalin Cirstoiu in
Google Scholar
PubMed
-
Patients diagnosed with soft tissue sarcoma (STS) present a number of challenges for physicians, due to the vast array of subtypes and aggressive tumor biology.
-
There is currently no agreed-upon management strategy for these tumors, which has led to the ongoing debate surrounding how frequently surveillance scans should be performed following surgery. However, advances in multidisciplinary care have improved patient outcomes over recent years.
-
The early detection of local recurrence reflects a more aggressive tumor, even in association with the same histopathologic entity.
-
Treating the local recurrence of extremity STS is a difficult clinical challenge. The goal should be to salvage limbs when possible, with treatments such as resection and irradiation, although amputation may be necessary in some cases. Regional therapies such as high-intensity, low-dose or interleukin-1 receptor antagonist treatment are appealing options for either definitive or adjuvant therapy, depending on the location of the disease’s recurrence.
-
The higher survival rate following late recurrence may be explained by variations in tumor biology. Since long-term survival is, in fact, inferior in patients with high-grade STS, this necessitates the implementation of an active surveillance approach.
Search for other papers by Daniel Kotrych in
Google Scholar
PubMed
Search for other papers by Andrea Angelini in
Google Scholar
PubMed
Search for other papers by Andrzej Bohatyrewicz in
Google Scholar
PubMed
Search for other papers by Pietro Ruggieri in
Google Scholar
PubMed
-
Satisfactory results in terms of functional and oncological outcomes can be obtained in sacral and pelvic malignant bone tumors.
-
Preoperative planning, adequate imaging, and a multidisciplinary approach are needed.
-
3D-printed prostheses have to fulfill several requirements: (i) mechanical stability, (ii) biocompatibility, (iii) implantability, and (iv) diagnostic compatibility.
-
In this review, we highlight current standards in the use of 3D-printed technology for sacropelvic reconstruction.
Orthopedics and Traumatology Department, University Emergency Hospital Bucharest, Bucharest, Romania
Search for other papers by Catalin Cirstoiu in
Google Scholar
PubMed
Orthopedics and Traumatology Department, University Emergency Hospital Bucharest, Bucharest, Romania
Search for other papers by Bogdan Cretu in
Google Scholar
PubMed
Orthopedics and Traumatology Department, University Emergency Hospital Bucharest, Bucharest, Romania
Search for other papers by Sergiu Iordache in
Google Scholar
PubMed
Orthopedics and Traumatology Department, University Emergency Hospital Bucharest, Bucharest, Romania
Search for other papers by Mihnea Popa in
Google Scholar
PubMed
Orthopedics and Traumatology Department, University Emergency Hospital Bucharest, Bucharest, Romania
Search for other papers by Bogdan Serban in
Google Scholar
PubMed
Orthopedics and Traumatology Department, University Emergency Hospital Bucharest, Bucharest, Romania
Search for other papers by Adrian Cursaru in
Google Scholar
PubMed
-
Bone metastases are difficult to treat surgically, necessitating a multidisciplinary approach that must be applied to each patient depending on the specifics of their case.
-
The main indications for surgical treatment are a lack of response to chemotherapy, radiation therapy, hormone therapy, immunotherapy, and bisphosphonates which is defined by persistent pain or tumor progression; the risk of imminent pathological bone fracture; and surgical treatment for single bone metastases.
-
An important aspect of choosing the right treatment for these patients is accurately estimating life expectancy. Improved chemotherapy, postoperative radiation therapy, and sustainable reconstructive modalities will increase the patient’s life expectancy.
-
The surgeon should select the best surgical strategy based on the primary tumor and its characteristics, the presence of single or multiple metastases, age, anatomical location, and the functional resources of the patient.
-
Preventive osteosynthesis, osteosynthesis to stabilize a fracture, resections, and reconstructions are the main surgical options for bone metastases.
-
Resection and reconstruction with a modular prosthesis remain the generally approved surgical option to restore functionality, increase the quality of life, and increase life expectancy.
-
Preoperative embolization is necessary, especially in the case of metastases of renal or thyroid origin. This procedure is extremely important to avoid complications, with a major impact on survival rates.
Search for other papers by Stephanie Marrannes in
Google Scholar
PubMed
Search for other papers by Klaas Victor in
Google Scholar
PubMed
Search for other papers by Nele Arnout in
Google Scholar
PubMed
Search for other papers by Tine De Backer in
Google Scholar
PubMed
Search for other papers by Jan Victor in
Google Scholar
PubMed
Search for other papers by Thomas Tampere in
Google Scholar
PubMed
-
Venous thromboembolism (VTE) is a well-known complication following orthopaedic surgery. The incidence of this complication has decreased substantially since the introduction of routine thromboprophylaxis. However, concerns have been raised about increased bleeding complications caused by aggressive thromboprophylaxis.
-
Attention has grown for aspirin as a safer thromboprophylactic agent following orthopaedic surgery.
-
A systematic review using MEDLINE, Embase and Web of Science databases was undertaken to compare the effectiveness of aspirin prophylaxis following knee surgery with the current standard prophylactic agents (low molecular weight heparin [LMWH], vitamin K antagonists and factor Xa inhibitors).
-
No significant difference in effectiveness of VTE prevention was found between aspirin, LMWH and warfarin. Factor Xa inhibitors were more effective, but increased bleeding complications were reported.
-
As evidence is limited and of low quality with substantial heterogeneity, further research with high-quality, adequately powered trials is needed.
Cite this article: EFORT Open Rev 2021;6:892-904. DOI: 10.1302/2058-5241.6.200120
